Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1 study of ABBV-787 in relapsed or refractory acute myeloid leukemia
jRCT2021230042Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ABBV-787 in acute myeloid leukemia (AML), sponsored by AbbVie Inc. Primary endpoints: Number of participants with adverse events, Maximum tolerated dose and 1 more. Started Nov 2023; status: completed.
02
Drugs
ABBV-787
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2021230042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021230042.